Table 1. Patient characteristics of all patients.
Characteristics | Before PSM | After PSM | ||||
---|---|---|---|---|---|---|
IMRT (n=75,%) | 3DCRT (n=98,%) | P value | 3DCRT (n=23,%) | IMRT (n=23,%) | P value | |
Sex | 0.152 | 0.475 | ||||
male | 45(60) | 69(70.4) | 19(82.6) | 17(73.9) | ||
female | 30(40) | 29(29.6) | 4(17.4) | 6(26.1) | ||
Stage | 0.813 | 0.765 | ||||
I | 48(64) | 61(62.2) | 14(60.9) | 13(56.5) | ||
II | 27(36) | 37(37.8) | 9(39.1) | 10(43.5) | ||
Age | 0.423 | 1.000 | ||||
≤60 | 68(90.7) | 85(86.7) | 20(87) | 20(87) | ||
>60 | 7(9.3) | 13(13.3) | 3(13) | 3(13) | ||
B symptoms | 0.436 | 0.697 | ||||
present | 27(36) | 41(41.8) | 5(21.7) | 3(13) | ||
absent | 48(64) | 57(58.2) | 18(78.3) | 20(87) | ||
Primary site | 0.584 | 1.000 | ||||
Nasal cavity | 59(78.7) | 81(82.7) | 19(82.6) | 20(87) | ||
Waldeyering's ring | 13(17.3) | 13(13.3) | 4(17.4) | 3(13) | ||
Hard plat | 2(2.7) | 2(2.0) | 0 | 0 | ||
buccal cavity | 1(1.3) | 1(1.0) | 0 | 0 | ||
gingiva | 0 | 1(1.0) | 0 | 0 | ||
ELTI | 0.315 | 0.300 | ||||
absent | 34(45.3) | 37 (37.8) | 7(30.4) | 4(17.4) | ||
present | 41(54.7) | 61 (62.2) | 16(69.6) | 19(82.6) | ||
LDH level | 0.465 | 1.000 | ||||
elevated | 17(22.7) | 17(17.3) | 3(13) | 2(8.7) | ||
normal | 58(77.3) | 81(82.7) | 20(87) | 21(91.3) | ||
PET/CT | 0.001 | 0.359 | ||||
absent | 27(36) | 85(86.7) | 13(56.5) | 16(69.6) | ||
present | 48(64) | 13(13.3) | 10(43.5) | 7(30.4) | ||
Induction chemotherapy | 0.001 | 0.369 | ||||
Asparaginase-based | 44(58.7) | 12(12.2) | 8(34.8) | 11(47.8) | ||
asparginase-absent | 31(41.3) | 86(87.8) | 15(65.2) | 12(52.2) | ||
Response to chemotherapy | 0.226 | 1.000 | ||||
CR | 32(42.7) | 33(33.3) | 10(43.5) | 10(43.5) | ||
Non-CR | 43(57.3) | 65(66.7) | 13(56.5) | 13(56.5) | ||
mIPI | 0.001 | 0.653 | ||||
0 | 22(29.3) | 23(23.5) | 4(17.4) | 3(20) | ||
1 | 21(28.0) | 31(31.6) | 10(43.5) | 8(26.7) | ||
2 | 23(30.7) | 32(32.7) | 5(21.7) | 10(36.7) | ||
3 | 9(12.0) | 12(12.2) | 4(17.4) | 2(16.7) |
Abbreviations: ELTI, extensive local tumor invasion; LDH, lactate dehydrogenase; CR, complete response; mIPI, stage-modified International Prognostic Index